Alector is a clinical-stage biotechnology company developing antibodies, enzymes, and RNA therapies to treat neurodegenerative diseases caused by misfolded proteins, lysosomal dysfunction, and immune pathway disruption. The company's proprietary Alector Brain Carrier platform uses receptor-mediated transport to deliver therapeutic molecules across the blood-brain barrier with improved brain penetration and potential for subcutaneous administration. Alector generates revenue through partnerships with large pharmaceutical companies, most notably a collaboration with GlaxoSmithKline that provides upfront payments and milestone-based compensation, while the company conducts clinical trials and advances preclinical programs toward regulatory approval with the goal of commercializing therapies either independently or through licensed partners.